<DOC>
	<DOC>NCT02667639</DOC>
	<brief_summary>The purpose of this fist in human study is to evaluate the safety and tolerability of RPH-104 in humans.</brief_summary>
	<brief_title>First in Human Study for RPH-104</brief_title>
	<detailed_description />
	<criteria>Healthy subjects. Male or female subjects between 18 and 35 years old (inclusive). Subject who has normal body weight as determined by a body mass index (BMI) of between 18 kg/m² and 28 kg/m² (inclusive) and within a body weight of ≥50kg and ≤120kg. Subjects with a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, dermatological, neurological, psychiatric, and hematological or immunological disorders Positive immunoglobulinM (IgM) antibodies against Epstein Barr virusviral capsid antigen (IgMantiEBVVCA) and Cytomegalovirus (CMV). Positive Quantiferon TBGold (TB) test. Positive to Human Immunodeficiency Virus1/2 antibody (HIV1/2Ab). Positive Hepatitis B surface antigen (HBsAg), or is Hepatitis C virus antibody (HCVAb).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>RPH-104</keyword>
	<keyword>RPH104</keyword>
</DOC>